| Species |
Human |
| Protein Construction |
Complement C3 (Ser23-Asn1663)
Accession # P01024 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
188.52 kDa |
| Apparent Molecular Weight |
Due to enzyme lysis and glycosylation, the protein migrates to 67-68 kDa, 110-115 kDa and 140-160 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Complement component 3 (C3), a pivotal molecule in the complement system, is an essential immune mediator in various diseases, including psoriasis. C3 deficiency promoted imiquimod-induced skin cell apoptosis and supported greater proportions of IFN-γ T cells in the inflamed tissues. |
| Synonyms |
Complement component 3;HSE-MSF;C3;CPAMD1;AHUS5;ARMD9;ASP;C3a;C3b;HEL-S-62p |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
